Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized, Double-Blind Study of MK-2214 in Early Alzheimer's Disease
jRCT2031250299Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing MK-2214 IV infusion with Placebo IV infusion (2 arms). Primary endpoints: Change from Baseline in Tau PET Standardized Uptake Value Ratio (SUVr), Number of Participants Who Experience One or More Adverse Events (AEs) and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
mk-2214
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on jRCT2031250299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250299.